Full-Time

Scientist – Analytical Development

Cell-Based Assays and ELISA

Updated on 3/14/2025

ArsenalBio

ArsenalBio

201-500 employees

Develops programmable cell therapies for cancer

Compensation Overview

$113.6k - $139.1kAnnually

Mid, Senior

Hayward, CA, USA

The job is onsite, indicating that the candidate must work in the Hayward office.

Category
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Excel/Numbers/Sheets
Requirements
  • Master’s degree with 5+ years of experience, or a Bachelor’s degree with 7+ years of experience, in Biotechnology, Bioprocess Engineering, Immunology, Molecular Biology, Biochemistry, or a related field, along with relevant industry experience
  • Excellent mammalian cell culture skills
  • Experience with immunological assays, such as cytokine/chemokine analysis (ELISA, Luminex or intracellular cytokine staining) and cytotoxicity
  • Proficiency using data analysis and interpretation using software such as GraphPad, Excel and JMP
  • Experience in technical development of analytical methods to support cell and gene therapy biologics and other advanced modalities in pre-clinical development and clinical stage settings (Phase II experience a plus)
  • Ability to learn new skills quickly to advance method development in support of drug product manufacturing
  • Strong problem-solving skills, with the ability to anticipate issues and identify solutions
  • Demonstrated ability to work as a team player in a collaborative environment and coordinate tasks across multiple projects to meet deadlines
  • Ability to lead the development of cell based assays successfully and handle multiple challenges under expedited timelines
  • Excellent communications, technical writing, presentation, written and verbal skills
  • Excellent organizational skills: Proactive management of multiple tasks of varying complexity simultaneously
  • Leadership to raise the level of the team's technical capabilities
  • Willingness to accept responsibilities outside of initial job description
Responsibilities
  • Independently design, test, and implement quality-based analytical assays to support the characterization and release of cell therapy products
  • Actively contribute to the development, and efficient execution of analytical methods for characterization of cell therapy process development, process manufacturing and drug products
  • Serve as an analytical SME to develop and perform in vitro cell-based analytical assays (cytotoxicity, cytokine, proliferation, etc.) for cell therapy product development
  • Provide analytical support for clinical-scale IND-enabling manufacturing operations including: Preparation of test methods, SOPs and technical development reports - Assay qualification, provide technical support and tech transfer to Quality Control in supporting of QC assay establishment and GMP lot release
  • Provide technical expertise and leadership within Analytical Development teams and in a matrix environment
  • Establish data tracking and trending analyses of process developmental runs and cGMP production runs, including evaluation of critical reagents and lot to lot variability, in order to improve process and assay standardization
  • Collaborate closely with other functions to enable effective and successful project development; actively engage in cross-functional collaboration with peers to overcome challenges
  • Organize, communicate, and present complex data sets to key stakeholders and senior management
  • Provide leadership and mentorship to junior SRAs
Desired Qualifications
  • Good understanding of cGMP environment, and Quality by Design (QBD) principles for assay development, qualification and validation preferred

ArsenalBio focuses on developing programmable cell therapies to treat solid tumor cancers. Their approach involves reprogramming cells to enhance their ability to fight cancer. The company is currently in the clinical stage, concentrating on research and development to bring these therapies to market. Their target clients are patients with solid tumor cancers, a significant segment of the cancer patient population. Unlike many competitors, ArsenalBio emphasizes a diverse team of experts from various scientific and clinical backgrounds, all working towards the common goal of creating effective cancer treatments. Once their therapies receive approval, they plan to generate revenue through sales to healthcare providers.

Company Size

201-500

Company Stage

Series C

Total Funding

$630M

Headquarters

San Francisco, California

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent $325 million funding boosts ArsenalBio's clinical development capabilities.
  • Partnerships with Thermo Fisher enhance ArsenalBio's manufacturing and technological capabilities.
  • Growing demand for personalized medicine aligns with ArsenalBio's programmable cell therapy focus.

What critics are saying

  • Emerging competition from companies like Allogene Therapeutics in CAR T-cell therapies.
  • High manufacturing costs may affect ArsenalBio's pricing and market competitiveness.
  • Regulatory scrutiny on gene-editing technologies could delay therapy approvals.

What makes ArsenalBio unique

  • ArsenalBio integrates CRISPR, synthetic biology, and machine learning for advanced cell therapies.
  • Their focus on solid tumors sets them apart in the CAR T-cell therapy space.
  • ArsenalBio's CITE technology enhances T-cell targeting and tumor microenvironment overcoming.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical, dental, & vision coverage

Virtual & telehealth options

Parental leave

Flexible work schedule

Flexible PTO

Mental health resources

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Arsenal Bio
Jan 6th, 2025
ArsenalBio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

South San Francisco, Calif. - January 6, 2025 - Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced that Ken Drazan, M.D., ArsenalBio's CEO and Chairman, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13, 2025, at 4 p.m. PST.

Bakersfield.com
Sep 16th, 2024
Nate Hardy to Join Arsenal Biosciences, Inc. as Chief Financial Officer

Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced that Nate Hardy will join its management team as Chief Financial Officer, effective October 7, 2024.

BioPharma Reporter
Sep 5th, 2024
ArsenalBio bags $325 million to develop CRISPR-engineered cell therapies

ArsenalBio bags $325 million to develop crispr-engineered cell therapies.

Arsenal Bio
Sep 4th, 2024
ArsenalBio Announces $325 Million Financing to Advance Programmable Cell Therapy Programs through Clinical Development • Arsenal Bio

Oversubscribed Series C welcomes multiple new investors South San Francisco, Calif. – September 4, 2024 – Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced the close of an oversubscribed $325 million Series C financing round. The funding round included new […]

CityBiz
Sep 4th, 2024
T. Rowe Price Joins $325 Million Financing for ArsenalBio

T. Rowe Price joins $325 million financing for ArsenalBio.